187 related articles for article (PubMed ID: 37237274)
1. Exploring the prognostic function of TMB-related prognostic signature in patients with colon cancer.
Zhao Y; Liang X; Duan X; Zhang C
BMC Med Genomics; 2023 May; 16(1):116. PubMed ID: 37237274
[TBL] [Abstract][Full Text] [Related]
2. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
[No Abstract] [Full Text] [Related]
3. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
4. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
Front Immunol; 2022; 13():881359. PubMed ID: 35911752
[TBL] [Abstract][Full Text] [Related]
5. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
[No Abstract] [Full Text] [Related]
6. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients.
Zheng Y; Wu R; Wang X; Yin C
Front Public Health; 2022; 10():860381. PubMed ID: 35462848
[TBL] [Abstract][Full Text] [Related]
8. MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method.
Li Z; Jiang L; Zhao R; Huang J; Yang W; Wen Z; Zhang B; Du G
Medicine (Baltimore); 2021 May; 100(21):e26068. PubMed ID: 34032736
[TBL] [Abstract][Full Text] [Related]
9. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel glycolysis-related gene signature for predicting the survival of patients with colon adenocarcinoma.
Yi K; Wu J; Tang X; Zhang Q; Wang B; Wang F
Scand J Gastroenterol; 2022 Feb; 57(2):214-221. PubMed ID: 34644216
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Four Cancer Stem Cell-Related Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Adenocarcinoma.
Li S; Chen R; Luo W; Lin J; Chen Y; Wang Z; Lin W; Li B; Wang J; Yang J
Comb Chem High Throughput Screen; 2022; 25(12):2070-2081. PubMed ID: 35048799
[TBL] [Abstract][Full Text] [Related]
12. Circadian Clock Genes Are Correlated with Prognosis and Immune Cell Infiltration in Colon Adenocarcinoma.
He A; Huang Z; Zhang R; Lu H; Wang J; Cao J; Feng Q
Comput Math Methods Med; 2022; 2022():1709918. PubMed ID: 35116071
[TBL] [Abstract][Full Text] [Related]
13. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
[TBL] [Abstract][Full Text] [Related]
14. A potential prognostic prediction model of colon adenocarcinoma with recurrence based on prognostic lncRNA signatures.
Jin L; Li C; Liu T; Wang L
Hum Genomics; 2020 Jun; 14(1):24. PubMed ID: 32522293
[TBL] [Abstract][Full Text] [Related]
15. Metabolism-related lncRNAs signature to predict the prognosis of colon adenocarcinoma.
Sun Y; Liu B; Xiao B; Jiang X; Xiang JJ; Xie J; Hu XM
Cancer Med; 2023 Mar; 12(5):5994-6008. PubMed ID: 36366731
[TBL] [Abstract][Full Text] [Related]
16. Genome‑scale analysis to identify potential prognostic microRNA biomarkers for predicting overall survival in patients with colon adenocarcinoma.
Wei HT; Guo EN; Liao XW; Chen LS; Wang JL; Ni M; Liang C
Oncol Rep; 2018 Oct; 40(4):1947-1958. PubMed ID: 30066920
[TBL] [Abstract][Full Text] [Related]
17. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of ferroptosis-associated gene signature in colon adenocarcinoma.
Miao YD; Kou ZY; Wang JT; Mi DH
World J Clin Cases; 2021 Oct; 9(29):8671-8693. PubMed ID: 34734046
[TBL] [Abstract][Full Text] [Related]
19. A Novel Pyroptosis-Related Gene Signature for Predicting the Prognosis and the Associated Immune Infiltration in Colon Adenocarcinoma.
Chen Z; Han Z; Nan H; Fan J; Zhan J; Zhang Y; Zhu H; Cao Y; Shen X; Xue X; Lin K
Front Oncol; 2022; 12():904464. PubMed ID: 35912258
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
